Free Trial

Zai Lab (ZLAB) Competitors

Zai Lab logo
$26.32 -1.70 (-6.07%)
Closing price 04:00 PM Eastern
Extended Trading
$26.56 +0.24 (+0.91%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZLAB vs. ASND, RDY, VTRS, ROIV, BBIO, MRNA, QGEN, ELAN, VRNA, and RVMD

Should you be buying Zai Lab stock or one of its competitors? The main competitors of Zai Lab include Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Moderna (MRNA), QIAGEN (QGEN), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

Zai Lab vs. Its Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Zai Lab. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 8 mentions for Zai Lab. Ascendis Pharma A/S's average media sentiment score of 0.50 beat Zai Lab's score of -0.12 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascendis Pharma A/S
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Zai Lab
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

41.7% of Zai Lab shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 5.0% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Zai Lab has a net margin of -49.68% compared to Ascendis Pharma A/S's net margin of -54.94%. Ascendis Pharma A/S's return on equity of 0.00% beat Zai Lab's return on equity.

Company Net Margins Return on Equity Return on Assets
Ascendis Pharma A/S-54.94% N/A -24.31%
Zai Lab -49.68%-27.32%-18.85%

Ascendis Pharma A/S has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.

Ascendis Pharma A/S currently has a consensus price target of $249.80, suggesting a potential upside of 23.66%. Zai Lab has a consensus price target of $56.35, suggesting a potential upside of 114.10%. Given Zai Lab's higher probable upside, analysts clearly believe Zai Lab is more favorable than Ascendis Pharma A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascendis Pharma A/S
1 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.94
Zai Lab
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

Zai Lab has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$490.75M25.39-$409.12M-$5.16-39.15
Zai Lab$427.80M6.88-$257.10M-$2.04-12.90

Summary

Ascendis Pharma A/S beats Zai Lab on 9 of the 17 factors compared between the two stocks.

Get Zai Lab News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZLAB vs. The Competition

MetricZai LabMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.13B$3.45B$6.19B$10.68B
Dividend YieldN/A2.26%5.71%4.82%
P/E Ratio-12.9023.4529.9129.71
Price / Sales6.88494.28590.38132.28
Price / CashN/A45.5737.0161.44
Price / Book3.4310.4012.046.60
Net Income-$257.10M-$52.62M$3.32B$276.82M
7 Day Performance-6.96%2.08%1.79%2.07%
1 Month Performance-18.99%10.84%6.28%2.62%
1 Year Performance-20.68%13.57%61.13%32.86%

Zai Lab Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZLAB
Zai Lab
2.6008 of 5 stars
$26.32
-6.1%
$56.35
+114.1%
-3.2%$3.13B$427.80M-12.901,869News Coverage
Analyst Forecast
Analyst Revision
ASND
Ascendis Pharma A/S
3.0078 of 5 stars
$208.43
-0.5%
$248.29
+19.1%
+57.4%$12.93B$393.54M-40.391,017Analyst Forecast
Gap Up
RDY
Dr. Reddy's Laboratories
2.6155 of 5 stars
$14.36
+0.1%
$16.95
+18.1%
-6.5%$11.97B$3.81B21.7527,811News Coverage
Positive News
Earnings Report
Analyst Forecast
Gap Up
VTRS
Viatris
3.1848 of 5 stars
$9.86
+1.2%
$10.40
+5.5%
-10.7%$11.36B$14.74B-3.4032,000Analyst Forecast
ROIV
Roivant Sciences
2.6451 of 5 stars
$16.21
+1.1%
$19.94
+23.0%
+55.9%$10.95B$29.05M-23.16860
BBIO
BridgeBio Pharma
4.6084 of 5 stars
$55.96
+0.8%
$63.94
+14.3%
+120.1%$10.61B$221.90M-13.68400News Coverage
Analyst Forecast
MRNA
Moderna
4.2736 of 5 stars
$26.74
-0.3%
$41.81
+56.4%
-50.8%$10.48B$3.24B-3.555,800Trending News
Analyst Forecast
QGEN
QIAGEN
3.9631 of 5 stars
$47.30
+1.0%
$49.40
+4.4%
+20.6%$10.41B$1.98B27.955,765Positive News
ELAN
Elanco Animal Health
2.7906 of 5 stars
$20.04
+1.4%
$19.14
-4.5%
+74.0%$9.82B$4.44B23.309,000News Coverage
Analyst Forecast
VRNA
Verona Pharma PLC American Depositary Share
1.0849 of 5 stars
$106.91
flat
$109.00
+2.0%
N/A$9.21B$42.28M-107.9930Positive News
RVMD
Revolution Medicines
4.3312 of 5 stars
$48.75
+1.1%
$74.64
+53.1%
+10.2%$9.02B$11.58M-10.83250Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ZLAB) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners